A carregar...
Development of Alkyne-Containing Pyrazolopyrimidines To Overcome Drug Resistance of Bcr-Abl Kinase
Despite the success of imatinib at inhibiting Bcr-Abl and treating chronic myelogenous leukemia (CML), resistance to the therapy occurs over time in patients. In particular, the resistance to imatinib caused by the gatekeeper mutation T315I in Bcr-Abl remains a challenge in the clinic. Inspired by t...
Na minha lista:
| Publicado no: | J Med Chem |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7475166/ https://ncbi.nlm.nih.gov/pubmed/26562217 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.jmedchem.5b01125 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|